Supply Chain Intelligence

Processa Pharmaceuticals, Inc. Supply Chain

PCSA supply chain intelligence for Processa Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

PCSA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

11Suppliers
1Customers
2Debt Items
0Related Chains

Processa Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 92% We enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop our products.
APOSENSE-LTD APOSENSE-LTD 90% 10.6 License Agreement with Aposense, Ltd. dated May 24, 2020
ELION ELION 90% On May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and Elion as a result of the Company's alleged breach thereof.
ELION-ONCOLOGY-INC ELION-ONCOLOGY-INC 90% 10.8 License Agreement with Elion Oncology, Inc.
SUN-PHARMACEUTICALS SUN-PHARMACEUTICALS 90% 10.2 License Option Agreement with Sun Pharmaceuticals
SUN-PHARMACEUTICALS-INDUSTRIES-LIMITED SUN-PHARMACEUTICALS-INDUSTRIES-LIMITED 90% We are required to pay Sun Pharma royalties, on a product by product basis, on future worldwide net sales, or pay a percentage of any sublicense revenue
YUHAN-CORPORATION YUHAN-CORPORATION 90% 10.7 License Agreement with Yuhan Corporation
CORLYST-LLC CORLYST-LLC 62% $ 2,834,405 (1) Research and development personnel costs include employee stock-based compensation expense of $ 17,144 and $ 46,720 for the three months ended March 31, 2026 and 2025, respectively. (…
OCUPHIRE-PHARMA-INC OCUPHIRE-PHARMA-INC 62% d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…
OVERVIEW-PROCESSA-PHARMACEUTICALS-INC OVERVIEW-PROCESSA-PHARMACEUTICALS-INC 62% d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…
TERM-SHEET-YUHAN-CORPORATION TERM-SHEET-YUHAN-CORPORATION 62% d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…

Processa Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
A-G-P-ALLIANCE-GLOBAL-PARTNERS A-G-P-ALLIANCE-GLOBAL-PARTNERS 90% 10.10 Sales Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners

Processa Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PCSA-DEBT-11696 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-03-31.
PCSA-DEBT-11695 Warrants outstanding: 100000 90% xbrl warrant detail from xbrl 2023-12-31.

Processa Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Processa Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
PCSA-OWNER-BANK-OF-AMERICA-CORP-DE BANK OF AMERICA CORP /DE/ 90% 13F overlay lists BANK OF AMERICA CORP /DE/ as top holder; 1 tracked holders.

Processa Pharmaceuticals, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
View PCSA supply chain intel →

Explore the full interactive supply chain map for Processa Pharmaceuticals, Inc..

Open PCSA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map